Brain scans reveal how CagriSema curbs cravings in overweight individuals
NCT ID NCT06267092
First seen Jan 09, 2026 · Last updated Apr 28, 2026 · Updated 17 times
Summary
This study looked at how a combination of two medicines, cagrilintide and semaglutide (called CagriSema), affects appetite and brain activity in 164 adults with overweight or obesity. Participants received either CagriSema, a dummy medicine, or no medicine, and researchers measured their hunger, fullness, and brain responses. The goal was to understand the mechanisms behind appetite control, not to test a cure or long-term treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité - Campus Charité Mitte - Charité Research Organisation GmbH
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.